Lactoferrin: A modulator for immunity against tuberculosis related granulomatous pathology

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Actor, Jeffrey K ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORD FACTOR; LACTOFERRIN;

ANIMAL; GRANULOMA; HUMAN; IMMUNOLOGY; MOUSE; PHYSIOLOGY; TUBERCULOSIS;

ANIMALS; CORD FACTORS; GRANULOMA; HUMANS; LACTOFERRIN; MICE; TUBERCULOSIS;

EID: 84953897324     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/409596     Document Type: Review

References (110)

1. P. E. M. Fine, "Herd immunity: history, theory, practice," Epidemiologic Reviews, vol. 15, no. 2, pp. 265-302, 1993.
2. L. Ramakrishnan, "Revisiting the role of the granuloma in tuberculosis," Nature Reviews Immunology, vol. 12, no. 5, pp. 352-366, 2012.
3. M. Silva Miranda, A. Breiman, S. Allain, F. Deknuydt, and F. Altare, "The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?" Clinical and Developmental Immunology, vol. 2012, Article ID 139127, 14 pages, 2012.
4. S. A. Khader, J. Rangel-Moreno, J. J. Fountain et al., "In amurine tuberculosis model, the absence of homeostatic chemokines delays granuloma formation and protective immunity," Journal of Immunology, vol. 183, no. 12, pp. 8004-8014, 2009.
5. A. M. Cooper and S. A. Khader, "Therole of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis," Immunological Reviews, vol. 226, no. 1, pp. 191-204, 2008.
6. I. M. Orme and R. J. Basaraba, "The formation of the granuloma in tuberculosis infection," Seminars in Immunology, vol. 26, no. 6, pp. 601-609, 2014.
7. I. M. Orme, R. T. Robinson, and A. M. Cooper, "The balance between protective and pathogenic immune responses in the TB-infected lung," Nature Immunology, vol. 16, no. 1, pp. 57-63, 2014.
8. J. K. Actor, M. Olsen, C. Jagannath, and R. L. Hunter, "Relationship of survival, organism containment, and granuloma formation in acute murine tuberculosis," Journal of Interferon and Cytokine Research, vol. 19, no. 10, pp. 1183-1193, 1999.
9. J. L. Flynn and J. Chan, "Whats good for the host is good for the bug," Trends in Microbiology, vol. 13, no. 3, pp. 98-102, 2005.
10. D. G. Russell, "Mycobacterium tuberculosis and the intimate discourse of a chronic infection," Immunological Reviews, vol. 240, no. 1, pp. 252-268, 2011.
11. R. L. Hunter, "Pathology of post primary tuberculosis of the lung: an illustrated critical review," Tuberculosis, vol. 91, no. 6, pp. 497-509, 2011.
12. R. L. Hunter, J. K. Actor, S.-A. Hwang, V. Karev, and C. Jagannath, "Pathogenesis of post primary tuberculosis:immunity and hypersensitivity in the development of cavities," Annals of Clinical and Laboratory Science, vol. 44, no. 4, pp. 365-387, 2014.
13. K. J. Welsh, R. L. Hunter, and J. K. Actor, "Trehalose 6, 6′-dimycolate-a coat to regulate tuberculosis immunopathogenesis," Tuberculosis, vol. 93, supplement, pp. S3-S9, 2013.
14. M.-J. Kim, H. C. Wainwright, M. Locketz et al., "Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism," EMBO Molecular Medicine, vol. 2, no. 7, pp. 258-274, 2010.
15. J. K. Actor, E. Breij, R. A. Wetsel, H. Hoffmann, R. L. Hunter Jr., and C. Jagannath, "A role for complement C5 in organism containment and granulomatous response during murine tuberculosis," Scandinavian Journal of Immunology, vol. 53, no. 5, pp. 464-474, 2001.
16. J. K. Actor, C. D. Leonard, V. E. Watson et al., "Cytokine mRNAexpression and serumcortisol evaluation duringmurine lung inflammation induced by Mycobacterium tuberculosis," Combinatorial Chemistry and High Throughput Screening, vol. 3, no. 4, pp. 343-351, 2000.
17. C. W. Borders, A. Courtney, K. Ronen et al., "Requisite role for complement C5 and the C5a receptor in granulomatous response to mycobacterial glycolipid trehalose 6, 6′-dimycolate," Scandinavian Journal of Immunology, vol. 62, no. 2, pp. 123-130, 2005.
18. R. L. Hunter, C. Jagannath, and J. K. Actor, "Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs," Tuberculosis, vol. 87, no. 4, pp. 267-278, 2007.
19. C. Jagannath, H. Hoffmann, E. Sepulveda, J. K. Actor, R. A. Wetsel, and R. L. Hunter Jr., "Hypersusceptibility of A/J mice to tuberculosis is in part due to a deficiency of the fifth complement component (C5)," Scandinavian Journal of Immunology, vol. 52, no. 4, pp. 369-379, 2000.
20. V. E. Watson, L. L. Hill, L. B. Owen-Schaub et al., "Apoptosis in Mycobacterium tuberculosis infection in mice exhibiting varied immunopathology," Journal of Pathology, vol. 190, no. 2, pp. 211-220, 2000.
21. R. H. Copenhaver, E. Sepulveda, L. Y. Armitige et al., "Amutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential," Infection and Immunity, vol. 72, no. 12, pp. 7084-7095, 2004.
22. S.-A. Hwang, R. Arora, M. L. Kruzel, and J. K. Actor, "Lactoferrin enhances efficacy of the BCG vaccine: comparison between two inbred mice strains (C57BL/6 and BALB/c)," Tuberculosis, vol. 89, supplement 1, pp. S49-S54, 2009.
23. S.-A. Hwang, K. Wilk, M. L. Kruzel, and J. K. Actor, "A novel recombinant human lactoferrin augments the BCGvaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice," Vaccine, vol. 27, no. 23, pp. 3026-3034, 2009.
24. S.-A. Hwang, K. M. Wilk, M. Budnicka et al., "Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis," Vaccine, vol. 25, no. 37-38, pp. 6730-6743, 2007.
25. S.-A. Hwang and J. K. Actor, "Lactoferrin modulation of BCGinfected dendritic cell functions," International Immunology, vol. 21, no. 10, pp. 1185-1197, 2009.
26. S.-A. Hwang, M. L. Kruzel, and J. K. Actor, "Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis," International Immunopharmacology, vol. 5, no. 3, pp. 591-599, 2005.
27. K. M. Wilk, S.-A. Hwang, and J. K. Actor, "Lactoferrin modulation of antigen-presenting-cell response to BCG infection," Postepy Higieny i Medycyny Doswiadczalnej, vol. 61, pp. 277-282, 2007.
28. S. A. Hwang, M. L. Kruzel, and J. K. Actor, "CHO expressed recombinant human lactoferrin as an adjuvant for BCG," International Journal of Immunopathology and Pharmacology, vol. 28, no. 4, pp. 452-468, 2015.
29. R. L. Perez, J. Roman, G. W. Staton Jr., and R. L. Hunter, "Extravascular coagulation and fibrinolysis in murine lung inflammation induced by the mycobacterial cord factor trehalose-6, 6-dimycolate," American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 2, pp. 510-518, 1994.
30. C. A. Behling, R. L. Perez, M. R. Kidd, G. W. Staton Jr., and R. L. Hunter, "Induction of pulmonary granulomas, macrophage procoagulant activity, and tumor necrosis factor-alpha by trehalose glycolipids," Annals of Clinical and Laboratory Science, vol. 23, no. 4, pp. 256-266, 1993.
31. G. S. Retzinger, S. C. Meredith, R. L. Hunter, K. Takayama, and F. J. Kezdy, "Identification of the physiologically active state of the mycobacterial glycolipid trehalose 6, 6′-dimycolate and the role of fibrinogen in the biologic activities of trehalose 6, 6′-dimycolate monolayers," Journal of Immunology, vol. 129, no. 2, pp. 735-744, 1982.
32. G. S. Retzinger, S. C. Meredith, K. Takayama, R. L. Hunter, and F. J. Kezdy, "The role of surface in the biological activities of trehalose 6, 6′-dimycolate. Surface properties and development of amodel system,"The Journal of Biological Chemistry, vol. 256, no. 15, pp. 8208-8216, 1981.
33. R. L. Perez, J. Roman, S. Roser et al., "Cytokine message and protein expression during lung granuloma formation and resolution induced by the mycobacterial cord factor trehalose-6, 6′-dimycolate," Journal of Interferon and Cytokine Research, vol. 20, no. 9, pp. 795-804, 2000.
34. R. L. Hunter, M. R. Olsen, C. Jagannath, and J. K. Actor, "Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease," Annals of Clinical and Laboratory Science, vol. 36, no. 4, pp. 371-386, 2006.
35. J. K. Actor, "Mycobacterial TDM: a coat to modulate post primary pathogenesis?" Mycobacterial Diseases, vol. 2, no. 1, article e106, 2012.
36. R. L. Hunter, M. Olsen, C. Jagannath, and J. K. Actor, "Trehalose 6, 6′-dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice," The American Journal of Pathology, vol. 168, no. 4, pp. 1249-1261, 2006.
37. A. N. Abbott, T. V. Guidry, K. J. Welsh et al., "11Beta-hydroxysteroid dehydrogenases are regulated during the pulmonary granulomatous response to the mycobacterial glycolipid trehalose-6, 6′-dimycolate," NeuroImmunoModulation, vol. 16, no. 3, pp. 147-154, 2009.
38. K. J. Welsh, A. N. Abbott, S.-A. Hwang et al., "A role for tumour necrosis factor-α, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6, 6′-dimycolate induced granulomatous response," Microbiology, vol. 154, no. 6, pp. 1813-1824, 2008.
39. A. Bekierkunst and E. Yarkoni, "Granulomatous hypersensitivity to trehalose-6, 6-dimycolate (cord factor) in mice infected with BCG," Infection and Immunity, vol. 7, no. 4, pp. 631-638, 1973.
40. H. Yamagami, T. Matsumoto, N. Fujiwara et al., "Trehalose 6, 6′-dimycolate (cord factor) ofMycobacterium tuberculosis induces foreign-body-and hypersensitivity-type granulomas in mice," Infection and Immunity, vol. 69, no. 2, pp. 810-815, 2001.
41. T. V. Guidry, R. L. Hunter Jr., and J. K. Actor, "Mycobacterial glycolipid trehalose 6, 6′-dimycolate-induced hypersensitive granulomas: contribution of CD4+ lymphocytes," Microbiology, vol. 153, no. 10, pp. 3360-3369, 2007.
42. E. Rhoades, F.-F. Hsu, J. B. Torrelles, J. Turk, D. Chatterjee, and D. G. Russell, "Identification and macrophage-activating activity of glycolipids released from intracellular Mycobacterium bovis BCG,"MolecularMicrobiology, vol. 48, no. 4, pp. 875-888, 2003.
43. M. M. Hossain and M.-N. Norazmi, "Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection-the double-edged sword?" BioMed Research International, vol. 2013, Article ID179174, 18 pages, 2013.
44. D. M. E. Bowdish, K. Sakamoto, M.-J. Kim et al., "MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis," PLoS Pathogens, vol. 5, no. 6, Article ID e1000474, 2009.
45. E. Mortaz, I. M. Adcock, P. Tabarsi et al., "Interaction of pattern recognition receptors withMycobacteriumtuberculosis," Journal of Clinical Immunology, vol. 35, no. 1, pp. 1-10, 2015.
46. D. G. Russell, "Who puts the tubercle in tuberculosis?" Nature Reviews Microbiology, vol. 5, no. 1, pp. 39-47, 2007.
47. H. Schoenen, B. Bodendorfer, K. Hitchens et al., "Cutting Edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalosedibehenate," Journal of Immunology, vol. 184, no. 6, pp. 2756-2760, 2010.
48. E. Ishikawa, T. Ishikawa, Y. S. Morita et al., "Direct recognition of themycobacterial glycolipid, trehalose dimycolate, by C-type lectinMincle," Journal of ExperimentalMedicine, vol. 206, no. 13, pp. 2879-2888, 2009.
49. I. Matsunaga and D. B. Moody, "Mincle is a long sought receptor formycobacterial cord factor," Journal of Experimental Medicine, vol. 206, no. 13, pp. 2865-2868, 2009.
50. K. Werninghaus, A. Babiak, O. Gross et al., "Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FclRγ-Syk-Card9-dependent innate immune activation," Journal of Experimental Medicine, vol. 206, no. 1, pp. 89-97, 2009.
51. S. LeibundGut-Landmann, O. Gross, M. J. Robinson et al., "Sykand CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17," Nature Immunology, vol. 8, no. 6, pp. 630-638, 2007.
52. J. Indrigo, R. L. Hunter Jr., and J. K. Actor, "Influence of trehalose 6, 6′-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages," Microbiology, vol. 148, no. 7, pp. 1991-1998, 2002.
53. J. Indrigo, R. L. Hunter Jr., and J. K. Actor, "Cord factor trehalose 6, 6′-dimycolate (TDM) mediates trafficking events duringmycobacterial infection ofmurine macrophages," Microbiology, vol. 149, no. 8, pp. 2049-2059, 2003.
54. J. K. Actor, M. Olsen, R. L. Hunter Jr., and Y.-J. Geng, "Dysregulated response to mycobacterial cord factor trehalose-6, 6′-dimycolate inCD1D-/- mice," Journal of Interferon and Cytokine Research, vol. 21, no. 12, pp. 1089-1096, 2001.
55. J. K. Actor, J. Indrigo, C. M. Beachdel et al., "Mycobacterial glycolipid cord factor trehalose 6, 6′-dimycolate causes a decrease in serum cortisol during the granulomatous response," Neuro-ImmunoModulation, vol. 10, no. 5, pp. 270-282, 2002.
56. A. N. Abbott, K. J. Welsh, S.-A. Hwang et al., "IL-6 mediates 11βhsd type 2 to effect progression of the mycobacterial cord factor trehalose 6, 6′-dimycolate-induced granulomatous response," NeuroImmunoModulation, vol. 18, no. 4, pp. 212-225, 2011.
57. T. V. Guidry, M. Olsen, K.-S. Kil, R. L. Hunter Jr., Y.-J. Geng, and J. K. Actor, "Failure of CD1D-/- mice to elicit hypersensitive granulomas to mycobacterial cord factor trehalose 6, 6′-dimycolate," Journal of Interferon and Cytokine Research, vol. 24, no. 6, pp. 362-371, 2004.
58. T. V. Guidry, R. L. Hunter Jr., and J. K. Actor, "CD3+ cells transfer the hypersensitive granulomatous response to mycobacterial glycolipid trehalose 6, 6′-dimycolate in mice," Microbiology, vol. 152, no. 12, pp. 3765-3775, 2006.
59. B. Lonnerdal and S. Iyer, "Lactoferrin: molecular structure and biological function," Annual Review of Nutrition, vol. 15, pp. 93-110, 1995.
60. L. Sanchez, M. Calvo, and J. H. Brock, "Biological role of lactoferrin," Archives of Disease in Childhood, vol. 67, no. 5, pp. 657-661, 1992.
61. P. Manzoni, M. Rinaldi, S. Cattani et al., "Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial," Journal of the American Medical Association, vol. 302, no. 13, pp. 1421-1428, 2009.
62. S. Baveye, E. Elass, J. Mazurier, G. Spik, and D. Legrand, "Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process," Clinical Chemistry and Laboratory Medicine, vol. 37, no. 3, pp. 281-286, 1999.
63. R. D. Baynes and W. R. Bezwoda, "Lactoferrin and the inflammatory response," Advances in Experimental Medicine and Biology, vol. 357, pp. 133-141, 1994.
64. M. Kocieba, M. Zimecki, M. Kruzel, and J. Actor, "The adjuvant activity of lactoferrin in the generation of DTH to ovalbumin can be inhibited by bovine serum albumin bearing alpha-Dmannopyranosyl residues," Cellular and Molecular Biology Letters, vol. 7, no. 4, pp. 1131-1136, 2002.
65. C. G. Turin, A. Zea-Vera, A. Pezo et al., "Lactoferrin for prevention of neonatal sepsis," Biometals, vol. 27, no. 5, pp. 1007-1016, 2014.
66. T. Siqueiros-Cendon, S. Arevalo-Gallegos, B. F. Iglesias-Figueroa, I. A. Garcia-Montoya, J. Salazar-Martinez, and Q. Rascon-Cruz, "Immunomodulatory effects of lactoferrin," Acta Pharmacologica Sinica, vol. 35, no. 5, pp. 557-566, 2014.
67. D. Latorre, F. Berlutti, P. Valenti, S. Gessani, and P. Puddu, "LF immunomodulatory strategies: mastering bacterial endotoxin," Biochemistry and Cell Biology, vol. 90, no. 3, pp. 269-278, 2012.
68. D. Legrand, "Lactoferrin, a key molecule in immune and inflammatory processes," Biochemistry and Cell Biology, vol. 90, no. 3, pp. 252-268, 2012.
69. S.-A. Hwang, K. M. Wilk, Y. A. Bangale, M. L. Kruzel, and J. K. Actor, "Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes," Medical Microbiology and Immunology, vol. 196, no. 3, pp. 171-180, 2007.
70. M. Zimecki, J. Mazurier, G. Spik, and J. A. Kapp, "Human lactoferrin induces phenotypic and functional changes in murine splenic B cells," Immunology, vol. 86, no. 1, pp. 122-127, 1995.
71. M. Zimecki, J. Artym, G. Chodaczek et al., "Immunoregulatory function of lactoferrin in immunosuppressed and autoimmune animals," Postepy Higieny i Medycyny Doswiadczalnej, vol. 61, pp. 283-287, 2007.
72. M. Zimecki and M. L. Kruzel, "Milk-derived proteins and peptides of potential therapeutic and nutritive value," Journal of Experimental Therapeutics and Oncology, vol. 6, no. 2, pp. 89-106, 2007.
73. M. Zimecki, R. Midzybrodzki, J. Mazurier, and G. Spik, "Regulatory effects of lactoferrin and lipopolysaccharide on LFA-expression on human peripheral blood mononuclear cells," Archivum Immunologiae et Therapiae Experimentalis, vol. 47, no. 4, pp. 257-264, 1999.
74. M. L. Kruzel and M. Zimecki, "Lactoferrin and immunologic dissonance: clinical implications," Archivum Immunologiae et Therapiae Experimentalis, vol. 50, no. 6, pp. 399-410, 2002.
75. W. I. Weis, M. E. Taylor, and K. Drickamer, "The C-type lectin superfamily in the immune system," Immunological Reviews, vol. 163, pp. 19-34, 1998.
76. W. I. Weis, K. Drickamer, and W. A. Hendrickson, "Structure of a C-type mannose-binding protein complexed with an oligosaccharide," Nature, vol. 360, no. 6400, pp. 127-134, 1992.
77. T. Zagulski, Z. Jarzabek, A. Zagulska, M. Jaszczak, I. E. Kochanowska, and M. Zimecki, "Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice," Archivum Immunologiae et Therapiae Experimentalis, vol. 49, no. 6, pp. 431-438, 2001.
78. M. Kruzel, Y. Harai, C. Chen, and A. Castro, "Role of lactoferrin in development of systemic inflammatory response syndrome (SIRS)," in Proceedings of the 2nd International Conference Progress in Intensive Care Medicine, pp. 11-12, Wroclaw, Poland, 1998.
79. M. L. Kruzel, Y. Harari, C.-Y. Chen, and G. A. Castro, "The gut: a key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice," in Advances in Lactoferrin Research, vol. 443 of Advances in Experimental Medicine and Biology, pp. 167-173, Springer, NewYork, NY, USA, 1998.
80. M. Kruzel, T. Zagulski, and M. Zimecki, "Lactoferrinandinsultinduced metabolic imbalance in humans and other animals," in Lactoferrin: Structure, Function and Applications: Proceedings of the 4th International Conference on Lactoferrin: Structure, Function and Applications, held in Sapporo, Japan 18-22 May 1999, pp. 301-311, ICS Elsevier, New York, NY, USA, 2000.
81. M. L. Kruzel, Y. Harari, C.-Y. Chen, and G. A. Castro, "Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice," Inflammation, vol. 24, no. 1, pp. 33-44, 2000.
82. E. Zaczynska, M. Kociba, E. Sliwinska, and M. Zimecki, "Bovine lactoferrin enhances proliferation of human peripheral blood lymphocytes and induces cytokine production in whole blood cultures," Advances in Clinical and Experimental Medicine, vol. 23, pp. 871-876, 2014.
83. Z. Wei, T. Nishimura, and S. Yoshida, "Characterization of glycans in a lactoferrin isoform, lactoferrin-a," Journal of Dairy Science, vol. 84, no. 12, pp. 2584-2590, 2001.
84. B.-K. Choi, J. K. Actor, S. Rios et al., "Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response," Glycoconjugate Journal, vol. 25, no. 6, pp. 581-593, 2008.
85. B. Samyn-Petit, J.-P. Wajda Dubos, F. Chirat et al., "Comparative analysis of the site-specific N-glycosylation of human lactoferrin produced in maize and tobacco plants," European Journal of Biochemistry, vol. 270, no. 15, pp. 3235-3242, 2003.
86. M. Zimecki, J. Artym, M. Kociba, M. Duk, and M. L. Kruzel, "The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro," Cellular and Molecular Biology Letters, vol. 19, no. 2, pp. 284-296, 2014.
87. J. K. Actor, S.-A. Hwang, and M. L. Kruzel, "Lactoferrin as a natural immune modulator," Current Pharmaceutical Design, vol. 15, no. 17, pp. 1956-1973, 2009.
88. M. L. Kruzel, J. K. Actor, I. Boldogh, and M. Zimecki, "Lactoferrin in health and disease," Postepy Higieny i Medycyny Doswiadczalnej, vol. 61, pp. 261-267, 2007.
89. S. Baveye, E. Elass, D. G. Fernig, C. Blanquart, J. Mazurier, and D. Legrand, "Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, Eselectin and ICAM-1, induced by the CD14-lipopolysaccharide complex," Infection and Immunity, vol. 68, no. 12, pp. 6519-6525, 2000.
90. C. S. Curran, K. P. Demick, and J. M. Mansfield, "Lactoferrin activates macrophages via TLR4-dependent and-independent signaling pathways," Cellular Immunology, vol. 242, no. 1, pp. 23-30, 2006.
91. P. Puddu, D. Latorre, M. Carollo et al., "Bovine lactoferrin counteracts Toll-Like receptor mediated activation signals in antigen presenting cells," PLoS ONE, vol. 6, no. 7, Article ID e22504, 2011.
92. T. M. Doherty and M. Arditi, "TB, or not TB:That is the question-does TLR signaling hold the answer?"The Journal of Clinical Investigation, vol. 114, no. 12, pp. 1699-1703, 2004.
93. M. A. Rahman, P. Sobia, N. Gupta, L. Van Kaer, and G. Das, "Mycobacterium tuberculosis subverts the TLR-2-MyD88 pathway to facilitate its translocation into the cytosol," PLoS ONE, vol. 9, no. 1, Article ID e86886, 2014.
94. J. Artym, M. Zimecki, and M. L. Kruzel, "Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin," International Immunopharmacology, vol. 4, no. 9, pp. 1149-1157, 2004.
95. G. Chodaczek, A. Saavedra-Molina, A. Bacsi, M. L. Kruzel, S. Sur, and I. Boldogh, "Iron-mediated dismutation of superoxide anion augments antigen-induced allergic inflammation: effect of lactoferrin," Postepy Higieny i Medycyny Doswiadczalnej, vol. 61, pp. 268-276, 2007.
96. M. Kruzel, Y. Harai, C. Chen, and A. Castro, "The Gut: a key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice," in Advances in Lactoferrin Research, G. Spik, D. Legrand, J. Mazurier, A. Pierce, and J.-P. Perraudin, Eds., vol. 443 of Advances in Experimental Medicine and Biology, pp. 167-173, Plenum Press, 1998.
97. M. L. Kruzel, A. Bacsi, B. Choudhury, S. Sur, and I. Boldogh, "Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma," Immunology, vol. 119, no. 2, pp. 159-166, 2006.
98. J. K. Actor, S.-A. Hwang, M. Olsen, M. Zimecki, R. L. Hunter Jr., and M. L. Kruzel, "Lactoferrin immunomodulation of DTH response in mice," International Immunopharmacology, vol. 2, no. 4, pp. 475-486, 2002.
99. S.-A. Hwang, M. L. Kruzel, and J. K. Actor, "Influence of bovine lactoferrin on expression of presentation molecules on BCGinfected bonemarrow derived macrophages," Biochimie, vol. 91, no. 1, pp. 76-85, 2009.
100. M. Zimecki, J. Mazurier, M. Machnicki, Z. Wieczorek, J. Montreuil, and G. Spik, "Immunostimulatory activity of lactotransferrin and maturation of CD4- CD8- murine thymocytes," Immunology Letters, vol. 30, no. 1, pp. 119-123, 1991.
101. K. J. Welsh, S.-A. Hwang, R. L. Hunter, M. L. Kruzel, and J. K. Actor, "Lactoferrin modulation of mycobacterial cord factor trehalose 6-6-dimycolate induced granulomatous response," Translational Research, vol. 156, no. 4, pp. 207-215, 2010.
102. M. L. Bourigault, N. Segueni, S. Rose et al., "Relative contribution of IL-1alpha, IL-1beta and TNF to the host response to Mycobacterium tuberculosis and attenuated M. bovis BCG," Immunity, Inflammation and Disease, vol. 1, no. 1, pp. 47-62, 2013.
103. C. Holscher, R. A. Atkinson, B. Arendse et al., "Aprotective and agonistic function of IL-12p40 in mycobacterial infection," The Journal of Immunology, vol. 167, no. 12, pp. 6957-6966, 2001.
104. M. Jacobs, L. Fick, N. Allie, N. Brown, and B. Ryffel, "Enhanced immune response in Mycobacterium bovis bacille calmette guerin (BCG)-infected IL-10-deficient mice," Clinical Chemistry and Laboratory Medicine, vol. 40, no. 9, pp. 893-902, 2002.
105. K. J. Welsh, S.-A. Hwang, S. Boyd, M. L. Kruzel, R. L. Hunter, and J. K. Actor, "Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology," Tuberculosis, vol. 91, supplement 1, pp. S105-S113, 2011.
106. M. L. Kruzel, J. K. Actor, M. Zimecki et al., "Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression," Journal of Biotechnology, vol. 168, no. 4, pp. 666-675, 2013.
107. Y. Shibata, J. Gabbard, M. Yamashita et al., "Heat-killed BCG induces biphasic cyclooxygenase 2+ splenic macrophage formation-role of IL-10 and bone marrow precursors," Journal of Leukocyte Biology, vol. 80, no. 3, pp. 590-598, 2006.
108. H. Yamada, E. Kuroda, S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita, "Prostaglandin E2 down-regulates viable Bacille Calmette-Guerin-induced macrophage cytotoxicity againstmurine bladder cancer cell MBT-2 in vitro," Clinical and Experimental Immunology, vol. 128, no. 1, pp. 52-58, 2002.
109. S. Hwang, M. L. Kruzel, and J. K. Actor, "Effects of CHOexpressed recombinant lactoferrins on mouse dendritic cell presentation and function," Innate Immunity, vol. 21, no. 5, pp. 553-561, 2015.
110. K. M. OShea, S.-A. Hwang, and J. K. Actor, "Immune activity of bcg infected mouse macrophages treated with a novel recombinant mouse lactoferrin," Annals of Clinical Lab Science, vol. 45, no. 5, pp. 403-410, 2015.